Biotech & Pharma

STAT+: Pharmalittle: We're reading about a Lilly weight loss trial, TrumpRx shortcomings, and more

Ali Nemati3 days ago28 sec read6 views

Eli Lilly's investigational drug retatrutide showed significant reductions in blood sugar and weight for diabetes patients, indicating potential benefits for obese individuals with type 2 diabetes. However, TrumpRx.gov failed to deliver consistently lower drug prices compared to those in the UK, highlighting its limitations in making medications more affordable. Content creators should focus on these medical advancements and healthcare policy implications when reporting on pharmaceutical news.

Read the full article at STAT Pharma

Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

Comments

RFK may replace entire panel of CDC vaccine advisors again, ally lets slip

A member of a federal vaccine advisory panel initially claimed that the panel had been disbanded and would be reconstituted again, though later retracted this statement; the current ACIP members, appointed by anti-vaccine advocate Robert F. Kennedy J...

Ali Nemati

Biotech & Pharma5 days ago34 sec read

STAT+: Pharmalittle: We're reading about Trump's drug pricing moves, a GSK asthma drug, and more

The White House is intensifying efforts to push Congress for a "most-favored nation" drug pricing policy despite Republican opposition, aiming to reduce medication costs below those in other countries. GSK's replacement of its popular asthma inhaler ...

Ali Nemati

Health & MedicineMar 1034 sec read

Opinion: STAT+: The Himsification of medicine

Hims & Hers launched a Super Bowl ad promoting preventive medicine services aimed at closing the health gap for middle-class Americans, but faced legal challenges when it announced plans to sell compounded oral semaglutide, leading to an FDA inve...

Ali Nemati

Biotech & PharmaMar 622 sec read

Post-Hoc Live: What will the US government do about China biotech?

The National Security Commission on Emerging Biotechnology warns the US is at risk of falling behind China in biotech innovation and will discuss policy recommendations to maintain leadership; the urgency stems from the commission's impending dissolu...

Ali Nemati

Biotech & PharmaFeb 2432 sec read

STAT+: Drugmakers lay out their legal arguments against Trump's drug pricing experiments

Pharmaceutical and biotech industries are opposing Trump administration's proposed Medicare pilot programs aimed at lowering drug prices by aligning them with international rates, signaling potential future legal challenges once the proposals are fin...

Ali Nemati

STAT+: Pharmalittle: We're reading about a Lilly weight loss trial, TrumpRx shortcomings, and more

Related Articles

RFK may replace entire panel of CDC vaccine advisors again, ally lets slip

STAT+: Pharmalittle: We're reading about Trump's drug pricing moves, a GSK asthma drug, and more

Opinion: STAT+: The Himsification of medicine

Post-Hoc Live: What will the US government do about China biotech?

STAT+: Drugmakers lay out their legal arguments against Trump's drug pricing experiments